Post Menopausal Osteoporosis Market

Key Highlights

• Up to 20% of bone loss can happen during these stages, and approximately 1 in 10 women over the age of 60 are affected by osteoporosis worldwide. 
• Traditional treatments like Parathyroid Hormone (PTH) analogs, hormone therapy, and denosumab have shown effectiveness in managing osteoporosis but come with notable side effects and FDA warnings, including recent concerns over denosumab-induced hypocalcemia. Osteoboost, a non-drug vibration therapy, offers a potential alternative with fewer side effects.
• Apart from targeted therapies like PROLIA and EVENITY, other available treatments for postmenopausal osteoporosis include anti-resorptive agents, anabolic agents, and mixed agents.
• Several other approved drugs in the past few years for postmenopausal osteoporosis include TYMLOS (Radius Health), DUAVEE (Pfizer), and others.
• The emerging landscape is not very robust. However, companies like Entera Bio (EB613) and Angitia Biopharmaceuticals (AGA2118) are evaluating their candidates for the treatment of postmenopausal osteoporosis.
• Although the present therapies have been effective, there is a major unmet need for specific treatment of postmenopausal osteoporosis. This void becomes an opportunity for aspiring companies to conduct trials and become successful.

DelveInsight's “Postmenopausal Osteoporosis – Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth analysis of postmenopausal osteoporosis epidemiology, market, and clinical development in postmenopausal osteoporosis. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the postmenopausal osteoporosis market trends in the United States, EU4 (Germany, France, Italy, and Spain ), the United Kingdom, and Japan.

The postmenopausal osteoporosis market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted postmenopausal osteoporosis market size from 2020 to 2034 in 7MM. The report also covers current postmenopausal osteoporosis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Postmenopausal Osteoporosis: Understanding and Treatment Algorithm

Postmenopausal Osteoporosis Overview

Osteoporosis is a metabolic bone disease marked by reduced bone mass and deterioration in the structure of bone tissue. It commonly leads to fractures, especially in the proximal femur (hip), vertebrae (spine), and distal radius (wrist). While these are the most typical fracture sites, many fractures in older adults are at least partially due to weakened bones.

The most prevalent form of the condition is postmenopausal osteoporosis, which arises from a deficiency in estrogen following menopause. This hormonal imbalance increases bone turnover by affecting all types of bone cells, leading to a mismatch between bone resorption and bone formation. Both trabecular (spongy) and cortical (compact) bone are impacted by this process, contributing to overall bone fragility.

Postmenopausal Osteoporosis Diagnosis

Osteoporosis screening is recommended for postmenopausal women and men over the age of 50 who are at increased risk. Risk assessment is based on the presence of clinical risk factors such as a history of fragility fractures, family history of osteoporosis, smoking, excessive alcohol consumption, early menopause, low Body Mass Index (BMI), or conditions contributing to secondary osteoporosis.

Diagnosis is often prompted by symptoms such as persistent pain or other physical signs. It is typically confirmed through laboratory tests, X-rays (roentgenograms), or bone scintigraphy. In more complex cases where standard methods are inconclusive, further evaluation may involve CT scans, MRI, or histological analysis of bone tissue samples.

Further details related to country-based variations in diagnosis are provided in the report

Postmenopausal Osteoporosis Treatment        

The treatment of postmenopausal osteoporosis involves estrogen replacement therapies, bisphosphonates, denosumab, calcium, and vitamin D, Selective Estrogen Receptor Modulators (SERMs) and other estrogen analogs, calcitonin, parathyroid hormone, vitamin K, anti-resorptive agents, anabolic agents, and mixed agents, etc. In cases when treatment methods, such as medication, exercise, and diet, do not help the effects of osteoporosis after three months of treatment, surgery is the only option. There are two minimally invasive surgical procedures for osteoporotic fractures of the spine, which include kyphoplasty and vertebroplasty.

Postmenopausal Osteoporosis Epidemiology

The postmenopausal osteoporosis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total prevalent cases of postmenopausal osteoporosis, total diagnosed prevalent cases of postmenopausal osteoporosis,  age-specific prevalent cases of postmenopausal osteoporosis, and total treatable cases of postmenopausal osteoporosis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• It is estimated that 75 million people in Europe, the US, and Japan are affected by osteoporosis.
• Among the eleven million individuals who are affected by osteoporosis in the US, over two-thirds are postmenopausal women, with estimates that one-half of this population will experience an osteoporosis-related fracture during their lifetime.
• Postmenopausal osteoporosis affects 35% of all women older than 50 years, with the percentage rising to 52% in women more than 70 years old.
• About one-third of post-menopausal women aged 50 and older in Italy have osteoporosis.
• The prevalence of osteoporosis in postmenopausal women aged 47 to 60 years was 20.2% in the lumbar vertebrae, while the highest prevalence of osteoporosis of 30% was found in the distal radius.

Postmenopausal Osteoporosis Recent Developments

• In September 2025, Shanghai Henlius Biotech and Organon announced that the U.S. FDA approved BILDYOS® (denosumab-nxxp) injection 60 mg/mL and BILPREVDA® (denosumab-nxxp) injection 120 mg/1.7 mL, biosimilars to PROLIA and XGEVA, respectively, for all indications of the reference products. BILDYOS is a RANK ligand (RANKL) inhibitor indicated for osteoporosis treatment in high-risk postmenopausal women and men, glucocorticoid-induced osteoporosis, and bone mass increase in prostate and breast cancer patients receiving specific therapies. Patients with advanced kidney disease face higher risks of severe hypocalcemia, requiring expert supervision before and during treatment.

Postmenopausal Osteoporosis Drug Chapters

The drug chapter segment of the postmenopausal osteoporosis report encloses a detailed analysis of postmenopausal osteoporosis marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into postmenopausal osteoporosis' pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Marketed Drugs

TYMLOS (abaloparatide): Radius Health

TYMLOS is a medicine approved for the treatment of osteoporosis in postmenopausal women and in men. It contains a protein that is similar to parathyroid hormone and increases bone formation and density. TYMLOS is an anabolic treatment for osteoporosis because it builds bone. In clinical trials, TYMLOS greatly reduced the chance of breaking a bone in post-menopausal women with osteoporosis.

In April 2017, subcutaneous TYMLOS received its first global approval, in the USA, for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

EVENITY (romosozumab): UCB Pharma/Amgen

The active substance in EVENITY, romosozumab, is a monoclonal antibody (a type of protein) that attaches to a specific target in the body called sclerostin. Sclerostin is a natural substance that plays an important role in regulating the formation and breakdown of bone. By attaching to sclerostin and blocking its action, romosozumab increases the formation of new bone tissue and reduces the breakdown of existing bone. This helps strengthen bones and reduce the risk of fractures.

Since 2004, Amgen and UCB have worked together under a collaboration and license agreement to research, develop, and market antibody products targeting the protein sclerostin. As part of this agreement, the two companies continued to collaborate on the development of romosozumab for the treatment of osteoporosis. In April 2019, the US FDA approved EVENITY to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture).

Note: Detailed current therapies assessment will be provided in the full report of postmenopausal osteoporosis.

Emerging Drugs

EB613 (PTH 1-34): Entera Bio

EB613 is being developed as the first oral, osteoanabolic once-daily tablet treatment for post-menopausal women with low Bone Mineral Density (BMD) and high-risk osteoporosis with no prior fracture. A placebo-controlled, dose-ranging Phase II study of EB613 met primary and secondary endpoints. The proposed registrational Phase III study for EB613 for osteoporosis is designed to meet the quantitative BMD thresholds proposed by SABRE.

In April 2024, Entera Bio announced that data from the Phase II Trial of EB613 the treatment of postmenopausal women with low BMD or osteoporosis, compared to placebo were published in the Journal of Bone and Mineral Research (JBMR).

AGA2118: Angitia Biopharmaceuticals

AGA2118 is a bispecific antibody that targets sclerostin and DKK1 and is in clinical development for the treatment of osteoporosis. Sclerostin and DKK1 are two critical, negative regulators of WNT signaling in osteoblasts and of bone metabolism. By targeting both proteins, AGA2118 is thought to prevent compensatory increase of either agent, aiming to improve the magnitude of bone mineral density gains in osteoporotic patients. Angitia wholly owns this bispecific antibody.

Angitia’s AGA2118 is currently under investigation in the ARTEMIS Phase II study.

Note: Detailed emerging therapies assessment will be provided in the final report.

Drug Class Insights

Current therapies for postmenopausal osteoporosis include RANKL inhibitors like PROLIA, which contains denosumab, the first and only approved RANKL antagonist. Denosumab acts by blocking the interaction between RANKL and RANK, thereby reducing osteoclast activity and strengthening bone.

More recently, therapies that target sclerostin have gained attention in both approved and investigational settings. Notable examples include the approved drug EVENITY and the investigational Phase II candidate AGA2118.

Postmenopausal Osteoporosis Market Outlook

The treatment landscape of postmenopausal osteoporosis comprises primarily pharmacological therapies, which are further characterized as anti-resorptive agents (i.e., bisphosphonates, estrogen agonist/antagonists [EAAs], estrogens, calcitonin, and denosumab), anabolic agents (i.e., teriparatide and abaloparatide), and mixed agents (i.e., Romosozumab). Apart from the mentioned pharmacotherapies, there are several other anti-resorptive treatment options to treat osteoporosis, such as estrogen replacement and selective estrogen receptor modulators. In addition, a few dietary supplements, such as calcium and vitamin D, also provide benefits to patients with postmenopausal osteoporosis. The current approved targeted therapies include EVENITY, TYMLOS, DUAVEE, etc. A recently approved biosimilar to PROLIA is JUBBONTI. 

Key players, such as Angitia Biopharmaceuticals, Entera Bio, and others, are evaluating their lead candidates in different stages of clinical development. They aim to investigate their products for the treatment of postmenopausal osteoporosis.

Key Findings

In January 2025, Pharmanovia entered into an exclusive in-licensing deal with Radius Health for abaloparatide, an osteoporosis therapy currently marketed in the US under the brand name TYMLOS. Under this, Pharmanovia was going to be responsible for clinical, regulatory, and commercial activities across key markets in the Asia Pacific (APAC) region.

Postmenopausal Osteoporosis Drug Uptake

The most commercially successful therapy for postmenopausal osteoporosis is denosumab (sold under the brand name PROLIA). It's a RANKL inhibitor administered via subcutaneous injection every six months and is widely prescribed for postmenopausal women at high risk of fractures. While other therapies like bisphosphonates (e.g., alendronate, risedronate) and anabolic agents (e.g., teriparatide, abaloparatide, romosozumab) are also available, denosumab has seen significant market share due to its efficacy and dosing convenience.

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025–2034, which depends on the competitive landscape, safety, and efficacy data, along with the order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Further detailed analysis of emerging therapies' drug uptake in the report…

Postmenopausal Osteoporosis Activities

The report provides insights into different therapeutic candidates in the Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Postmenopausal therapies.

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including Medical/scientific writers, Professors, and Others.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Harvard Medical School, University Hospital Amiens, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or postmenopausal osteoporosis market trends.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of postmenopausal osteoporosis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the postmenopausal osteoporosis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM postmenopausal osteoporosis market.

Postmenopausal Osteoporosis Report Insights

• Patient Population
• Therapeutic Approaches
• Postmenopausal Osteoporosis Pipeline Analysis
• Postmenopausal Osteoporosis Market Size and Trends
• Existing and future Market Opportunity

Postmenopausal Osteoporosis Report Key Strengths

• Ten-Year Forecast
• 7MM Coverage
• Postmenopausal Osteoporosis Epidemiology Segmentation
• Key Cross Competition
• Conjoint analysis
• Drugs Uptake and Key Market Forecast Assumptions

Postmenopausal Osteoporosis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

• What is the historical and forecasted postmenopausal osteoporosis patient pool/patient burden in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Which combination of treatment approaches will have a significant impact on the postmenopausal osteoporosis drug treatment market size?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the current and emerging options for the treatment of postmenopausal osteoporosis?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?
• How many key players are developing therapies for postmenopausal osteoporosis?
• Which drug is the major contributor postmenopausal osteoporosis market by 2034?

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the postmenopausal osteoporosis market.
• Insights on patient burden/disease Incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.